Brigatinib (Alunbrig)


Indications for Prior Authorization:

  • Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib

Patients must meet the following criteria for the indication(s) above:

  • Prescribed by an oncologist, AND
  • The patient has metastatic NSCLC that is anaplatic lymphoma kinase (ALK)-positive, AND
  • The patient has tried and failed Xalkori and Zykadia


  • 90 mg orally once daily for the first 7 days;
  • if 90 mg is tolerated during the first 7 days, increase the dose to 180 mg orally once daily
  • If treatment with Alunbrig is interrupted for 14 days or longer for reasons other than adverse reactions, resume treatment at 90 mg once daily for 7 days before increasing to the previously tolerated dose


  • 1 year
WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.